Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers
Aim: The work describes enhanced bioavailability of paliperidone palmitate through transdermal delivery using nanostructured lipid carriers (NLC). Materials & methods: NLCs were formulated by nanoprecipitation method followed by incorporation in transdermal patch and physicochemical characterization. Results: NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV. In vitro and ex vivo studies indicated zero-order controlled drug release from NLCs and transdermal patch up to 48 h. Pharmacokinetic studies indicated 1.76-fold enhanced bioavailability by transdermal route as compared with oral drug delivery. Conclusion: From the results, it was concluded that drug-loaded NLCs-transdermal patch is promising drug delivery system for poorly bioavailable drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 12(2021), 8 vom: 04. Aug., Seite 583-596 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raval, Shilpa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioavailability |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 02.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2021-0036 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328317055 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328317055 | ||
| 003 | DE-627 | ||
| 005 | 20231225202705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0036 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328317055 | ||
| 035 | |a (NLM)34286598 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raval, Shilpa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 02.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The work describes enhanced bioavailability of paliperidone palmitate through transdermal delivery using nanostructured lipid carriers (NLC). Materials & methods: NLCs were formulated by nanoprecipitation method followed by incorporation in transdermal patch and physicochemical characterization. Results: NLCs showed high percentage entrapment efficiency of 83.44 ± 0.8%, drug loading of 24.75 ± 1.10% (w/w), particle size of 173.8 ± 3.25 nm, polydispersity index of 0.143 ± 0.05 and zeta potential of -15.9 ± 0.75 mV. In vitro and ex vivo studies indicated zero-order controlled drug release from NLCs and transdermal patch up to 48 h. Pharmacokinetic studies indicated 1.76-fold enhanced bioavailability by transdermal route as compared with oral drug delivery. Conclusion: From the results, it was concluded that drug-loaded NLCs-transdermal patch is promising drug delivery system for poorly bioavailable drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a nanostructured lipid carriers | |
| 650 | 4 | |a paliperidone palmitate | |
| 650 | 4 | |a schizophrenia | |
| 650 | 4 | |a transdermal | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Paliperidone Palmitate |2 NLM | |
| 650 | 7 | |a R8P8USM8FR |2 NLM | |
| 700 | 1 | |a Jani, Parva |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Pravin |e verfasserin |4 aut | |
| 700 | 1 | |a Thakkar, Parth |e verfasserin |4 aut | |
| 700 | 1 | |a Sawant, Krutika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 12(2021), 8 vom: 04. Aug., Seite 583-596 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:8 |g day:04 |g month:08 |g pages:583-596 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2021-0036 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 8 |b 04 |c 08 |h 583-596 | ||